The latest research news in genetics and genomics.
The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.
The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
